用于快速、轻松地从血浆/血清样品中纯化循环 RNA 和外泌体 RNA
血浆/血清 RNA 纯化试剂盒
用于快速、轻松地从血浆/血清样品中纯化循环 RNA 和外泌体 RNA
Register today to receive an exclusive 15% off* on your first order.
概述
这些试剂盒提供了一种快速、可靠和方便的方法,利用便捷的旋转柱法纯化和浓缩优质、高纯度和无抑制剂的无细胞循环和外泌体 RNA。这些试剂盒可以从新鲜或冷冻的血清或血浆样本中纯化 RNA,这些样本都是用 EDTA 或柠檬酸盐采集的血液。不应使用肝素采血制备的血浆样本,因为肝素会严重干扰许多下游应用,如 RT-PCR。纯化的血浆/血清 RNA 与所有下游应用完全兼容,包括 PCR、qPCR、甲基化敏感反转录 qPCR、反转录 PCR、Northern 印迹、RNase 保护和引物延伸、表达阵列检测和 NGS。
背景
血浆/血清中不含细胞的循环 RNA 或外泌体 RNA 有可能为某些癌症和疾病提供生物标志物。外泌体是一种 40 - 150 nm 的膜囊泡,由大多数细胞类型分泌。外泌体可存在于唾液、血液、尿液、羊水和恶性腹水等生物液体中。最近有越来越多的证据表明,这些囊泡充当着细胞信使的角色,向体内遥远的细胞和组织传递信息。这些外泌体可能在介导对感染性病原体和肿瘤的适应性免疫反应、组织修复、神经通信和病原蛋白转移方面发挥功能性作用。因此,外泌体 RNA 可作为包括癌症在内的各种疾病的生物标记物。由于外泌体包裹的 RNA 分子不会被 RNAses 降解,因此可以从血浆或血清等生物液体中有效地回收。
血浆/血清 RNA 纯化迷你试剂盒
该试剂盒可从新鲜或冷冻的血清或血浆样本中纯化 RNA,样本量从 50 µL 到 200 µL 不等。纯化的血浆/血清 RNA 会以 10 µL 至 25 µL 的灵活最终体积进行洗脱。
血浆/血清 RNA 纯化 Midi 试剂盒
它采用双柱方法,可从新鲜或冷冻的血清或血浆样本中纯化 RNA,这些样本是用 EDTA 或柠檬酸盐采集的血液,体积从 250 µL 到 1.5 mL 不等。第一个色谱柱将处理大量输入的体液,然后在迷你色谱柱上进行浓缩,最终洗脱 50 µL 至 100 µL。
血浆/血清 RNA 纯化 Maxi 试剂盒
该试剂盒可从新鲜或冷冻的血清或血浆样本中纯化 RNA,这些样本是用 EDTA 或柠檬酸盐采集的血液,体积从 2 mL 到 5 mL 不等。第一个色谱柱将处理大量输入的体液,然后在迷你色谱柱上进行浓缩,最终洗脱 50 µL 至 100 µL。
纯化 EV 和外泌体后分离 RNA
用于超速离心、Exoquick 和过滤
| 类别号 | 名称 | 洗脱量 | 血浆/血清 | 尿液 | 细胞培养基 |
|---|---|---|---|---|---|
| 55000 | 血浆/血清 RNA 纯化迷你试剂盒 | 10 à 25 µL | 50 µL à 1 mL | 250 µL à 1 mL | 5 à 10 mL |
| 35300 | 总 RNA 纯化微型试剂盒 | 20 à 50 µL | 1 à 4 mL | 2 à 10 mL | 10 à 20 mL |
| 17200 | 总 RNA 纯化试剂盒 | 50 à 100 µL | 4 à 10 mL | 11 à 30 mL | 20 à 35 mL |
细节
Supporting Data
Figure 1. Purification of circulating RNA from different plasma volumes.
Norgen's Plasma/Serum RNA Purification Mini Kit was used to purify circulating RNA from 50 µL, 100 µL and 200 µL plasma prepared from blood collected on EDTA. Three microlitres of the purified RNA was then used as the template in RT-qPCR reactions to detect miR-21 (Figure 1A) and the housekeeping 5S rRNA transcript (Figure 1B). The relative amount of both the miR-21 (Figure 1A) and the 5S rRNA transcript (Figure 1B) is linearly increasing with increasing the sample input volume.
Figure 2. Eluting purified circulating RNA into different elution volumes.
Norgen’s Plasma/Serum RNA Purification Mini Kit was used to purify circulating RNA from 200 µL plasma prepared from blood collected on EDTA and eluted in 10 µL, 15 µL, and 25 µL. Three microlitres of the purified RNA was then used as the template in RT-qPCR reactions to detect miR-21 (Figure 2A) and the housekeeping 5S rRNA transcript (Figure 2B). The relative amount of both the miR-21 (Figure 2A) and the 5S rRNA transcript (Figure 2B) is increasing with increasing the elution volume indicating the efficient concentration of the plasma circulating RNA in a very low elution volume.
Figure 3. Effective and consistent detection of miRNA from plasma.
Norgen's Plasma/Serum RNA Purification Mini Kit can effectively isolate miRNA from plasma. Circulating miRNA was isolated from 200 µL plasma using Norgen's Plasma/Serum RNA Purification Mini Kit, competitor Q's kit and competitor E's kit. Circulating miRNA was isolated from 600 µL using competitor A's kit. Stem loop RT-qPCR using primers specific to miR-21 was performed. In brief, 1 microliter of the 15 µL RNA purified using Norgen's Plasma/Serum RNA Purification Mini Kit, competitor Q's kit and 3.3 microliters of the 50 µL purified RNA using competitor E's kit and competitor A's kit was then subjected to a 20 µL reverse transcription using miR-21 stem-loop reverse primer. Three microliters of the reverse transcription was used in a 20 µL real-time PCR reaction with primers to detect the human miR-21. Norgen's Plasma/Serum RNA Purification Mini Kit showed the most consistent and the highest recovery of the miR-21 transcripts as compared to the other isolation methods. The recovery of the miRNA from 200 µL plasma using Norgen's kit was higher than that recovered from RNA purified from 600 µL using competitor A's kit.
Figure 4. Small RNA Sequencing from as little as 50 µL of Plasma.
Norgen Biotek has developed an effective pipeline for small RNA sequencing from small volumes of plasma/serum. RNA can be effectively and consistently recovered from as little as 50 µL of plasma using Norgen's patented sample preparation technology (example shown here with Plasma/Serum RNA Purification Mini Kit, Cat. 55000). Panel A shows that the number of microRNA detected from 50 or 200 µL of plasma was almost identical to that of 4 mL. Panel B is a Venn diagram showing that of the microRNAs identified, the majority are detected in all volumes of plasma input from 50 µL to 4 mL. In fact, the scatter plots in Panel C show that the relative expression level of each microRNA detected was highly correlated between 50 or 200 µL of plasma and 4 mL plasma.
Figure 5. High Degree of Overlapping of miRNA profile between Urine and Plasma.
Plasma and mid-stream urine was collected from three different healthy individuals. RNA was isolated from 20 mL of each urine sample using Norgen's Urine Exosomal RNA Purification Kit (Cat. 47200) and 200 µL of each plasma sample using Norgen's Plasma/Serum RNA Purification Mini Kit (Cat. 55000). Small RNA Libraries were then generated using an Illumina TruSeq Small RNA Library Preparation Kit and subsequently sequenced on an Illumina MiSeq system. The list of mapped miRNAs from plasma and urine from the same individual was then compared. The Venn diagrams showed that the miRNA profiles have high degree of overlapping between urine and plasma within each individual.
Figure 6. Increased Diversity of Other Small RNA Species (Piwi-Interacting) in Urine.
Plasma and mid-stream urine was collected from three different healthy individuals. RNA was isolated from 20 mL of each urine sample using Norgen's Urine Exosomal RNA Purification Kit (Cat. 47200) and 200 µL of each plasma sample using Norgen's Plasma/Serum RNA Purification Mini Kit (Cat. 55000). Small RNA Libraries were then generated using an Illumina TruSeq Small RNA Library Preparation Kit and subsequently sequenced on an Illumina MiSeq system. The above chart showed that the relative proportion of piwi-interacting RNA (piRNA) was consistently higher in urine.
Figure 7. Better Diversity of miRNA Detected from HeLa Cells using Illumina Small RNA Next Gen Sequencing.
Norgen's Total RNA Purification Kit isolates miRNA from HeLa cells with better diversity than a leading competitor. Total RNA including miRNA was isolated from 1 million HeLa cells using Norgen's Total RNA Purification Kit and Competitor Q's leading miRNA Kit, and was applied to Illumina Small RNA Next Gen Sequencing on a MiSeq sequencer. Panel A showed that Norgen’s Total RNA Purification Kit recovers a higher number of miRNAs than the competitor. In particular, the higher diversity is achieved with a faster and simpler procedure in as little as 20 minutes of RNA sample preparation time without the use of phenol. Panel B is a scatter plot of the average RPM (reads per million) of the miRNAs detected to compare Norgen and the competitor’s recovery of miRNA. Norgen’s Total RNA Purification Kit recovered a significantly higher number of miRNAs that have higher RPM, as summarized in the graph insert as well as in Panel C.
Figure 8. Purification of cell-free circulating RNA and exosomal RNA from different plasma volumes.
Norgen’s Plasma/Serum RNA Purification Midi Kit (Cat# 56100) was used to purify cell-free circulating and exosomal RNA from 0.25 mL, 0.75 mL and 1.5 mL plasma prepared from blood collected on citrate as an anticoagulant. Two microlitres of the purified RNA was then used as the template in RT-qPCR reactions to assess the amplification of the (A) housekeeping 5S rRNA transcript and (B) miR-21. The average Ct value for both the 5S rRNA transcript and the miR-21 is linearly decreasing with increasing the sample input volume.
Figure 9. Linearity of RNA purified from increasing plasma volumes using Norgen’s Plasma/Serum RNA Purification Midi Kit.
Norgen’s Plasma/Serum RNA Purification Midi Kit (Cat# 56100) was used to purify RNA from 0.25 mL, 0.7 mL and 1.5 mL plasma prepared from blood collected on citrate as an anticoagulant. Two microlitres of the purified RNA was then used as the template in RT-qPCR reactions to assess the linearity of (A) the housekeeping 5S rRNA transcript and (B) miR-21 from the different plasma volumes. Norgen’s Plasma/Serum RNA Purification Midi Kit was able to recover 97% of both the 5S rRNA transcript and the miR-21 transcript from 0.75 mL plasma relative to the amount that is present in 0.35 mL plasma. Moreover, 95% of the 5S rRNA transcript and the miR-21 was recovered from 1.5 mL plasma relative to the amount that is present in 0.75 mL plasma.
Figure 10. Determination of the amount of inhibition present in plasma RNA samples when detecting the human 5S transcript and miR-21.
RNA was isolated from 0.25 mL, 0.75 mL and 1.5 mL plasma using Norgen’s Plasma/Serum RNA Purification Midi Kit (Cat# 56100). Increasing volumes of the elution (2, 4 and 8 µL) were used in a 20 µL reverse transcription reaction followed by qPCR amplification reaction to observe any decrease in Ct value. An increase in Ct values with increasing amount of template would be a clear indication of PCR inhibitors present in the sample. An increase in the PCR input volume used as a template in the reverse transcription reaction did not affect the Ct value generated from the qPCR amplification for both (A) 5S rRNA transcript and (B) miR-21. In fact the Ct values tend to decrease with increasing the PCR input volume indicating that RNA purified from plasma using Norgen’s kit is free of the common inhibitors usually present in plasma.
Figure 11. Purification of cell-free circulating RNA and exosomal RNA from different plasma volumes.
Norgen’s Plasma/Serum RNA Purification Maxi Kit (Cat# 56200) was used to purify cell-free circulating and exosomal RNA from 1.5 mL, 3 mL and 5 mL plasma prepared from blood collected on citrate as an anticoagulant. Two millilitres of the purified RNA was then used as the template in RT-qPCR reactions to assess the amplification of (A) the housekeeping 5S rRNA transcript and (B) miR-21. The average Ct value for both the 5S rRNA transcript and the miR-21 is linearly decreasing with increasing the sample input volume.
Figure 12. Linearity of RNA purified from increasing plasma volumes using Norgen’s Plasma/Serum RNA Purification Maxi Kit.
Norgen’s Plasma/Serum Cell-Free Circulating and Exosomal RNA Purification Maxi Kit (Cat# 56200) was used to purify RNA from 1.5 mL, 3 mL and 5 mL plasma prepared from blood collected on citrate as an anticoagulant. Two microlitres of the purified RNA was then used as the template in RT-qPCR reactions to assess the linearity of (A) the housekeeping 5S rRNA transcript and (B) miR-21 from the different plasma volumes. Norgen’s Plasma/Serum RNA Purification Maxi Kit was able to recover 92% of the 5S rRNA transcript from 3 mL plasma relative to the amount that is present in 1.5 mL plasma. Moreover, 90% of the 5S rRNA transcript was recovered from 5 mL plasma relative to the amount that is present in 3 mL plasma. As for miR-21, Norgen’s Plasma/Serum RNA Purification Maxi Kit was able to recover 91% of miR-21 from 3 mL plasma relative to the amount that is present in 1.5 mL plasma. Furthermore, 90% of miR-21 was recovered from 5 mL plasma relative to the amount that is present in 3 mL plasma.
Figure 13. Determination of the amount of inhibition present in plasma RNA samples when detecting the human 5S transcript and miR-21.
DNA was isolated from 1.5 mL, 3 mL and 5 mL plasma using Norgen’s Plasma/Serum RNA Purification Maxi Kit (Cat# 56200). Increasing volumes of the elution (2, 4 and 8 µL) were used in a 20 µL reverse transcription reaction followed by qPCR amplification reaction to observe any decrease in Ct value. An increase in Ct values with increasing amount of template would be a clear indication of PCR inhibitors present in the sample. An increase in the PCR input volume used as a template in the reverse transcription reaction did not affect the Ct value generated from the qPCR amplification for both (A) 5S rRNA transcript and (B) miR-21. In fact the Ct. values tend to decrease with increasing the PCR input volume indicating that RNA purified from plasma using Norgen’s kit is free of the common inhibitors usually present in plasma.
支持数据
图 1.从不同容量的血浆中纯化循环 RNA。Norgen 血浆/血清 RNA 纯化迷你试剂盒用于从 50 µL、100 µL 和 200 µL 经 EDTA 采集的血浆中纯化循环 RNA。然后将 3 μL 纯化的 RNA 用作 RT-q 聚合酶链式反应的模板,以检测 miR-21(图 1A)和看家 5S rRNA 转录本(图 1B)。随着样本输入量的增加,miR-21(图 1A)和 5S rRNA 转录本(图 1B)的相对量呈线性增加。
图 2.将纯化的循环 RNA 洗脱到不同的洗脱体积中。Norgens 血浆/血清 RNA 纯化迷你试剂盒用于从用 EDTA 采集的 200 µL 血浆中纯化循环 RNA,洗脱液分别为 10 µL、15 µL 和 25 µL。然后将 3 μL 纯化的 RNA 用作 RT-q 聚合酶链式反应的模板,以检测 miR-21(图 2A)和看家 5S rRNA 转录本(图 2B)。随着洗脱体积的增加,miR-21(图 2A)和 5S rRNA 转录本(图 2B)的相对含量也在增加,这表明血浆循环 RNA 在极低的洗脱体积内得到了有效浓缩。
图 3.从血浆中有效、一致地检测 miRNA。Norgen 的血浆/血清 RNA 纯化迷你试剂盒能有效地从血浆中分离 miRNA。使用 Norgen 的血浆/血清 RNA 纯化 迷你试剂盒、竞争对手 Q 的试剂盒和竞争对手 E 的试剂盒从 200 µL 血浆中分离循环 miRNA。使用竞争对手 A 的试剂盒从 600 µL 中分离循环 miRNA。使用 miR-21 的特异性引物进行了干环 RT-q 聚合酶链式反应。简而言之,使用 Norgen 的血浆/血清 RNA 纯化迷你试剂盒(竞争对手 Q 的试剂盒)纯化的 15 µL RNA 中的 1 µL,以及使用竞争对手 E 的试剂盒和竞争对手 A 的试剂盒纯化的 50 µL RNA 中的 3.3 µL,然后使用 miR-21 茎环反向引物进行 20 µL 反转录。在 20 µL 的实时聚合酶链式反应中使用了 3 µL 的反转录产物和引物来检测人类 miR-21。与其他分离方法相比,Norgen 的血浆/血清 RNA 纯化迷你试剂盒对 miR-21 转录本的回收率最高,也最稳定。使用 Norgen 试剂盒从 200 µL 血浆中回收的 miRNA 高于使用竞争对手 A 试剂盒从 600 µL RNA 中纯化的回收率。
图 4.对低至 50 µL 血浆的小 RNA 进行测序。Norgen Biotek 开发了一种有效的管道,可对小体积血浆/血清进行小 RNA 测序。使用 Norgen 已获专利的样本制备技术,可从少至 50 µL 的血浆中有效、稳定地回收 RNA(此处以血浆/血清 RNA 纯化迷你试剂盒为例,类别号:55000)。面板 A 显示,从 50 或 200 µL 的血浆中检测到的 microRNA 数量与 4 mL 的几乎相同。面板 B 是一张文氏图,显示在已确定的 microRNA 中,大多数都能在从 50 µL 到 4 mL 的所有血浆输入量中检测到。事实上,C 组的散点图显示,50 或 200 µL 血浆与 4 mL 血浆之间检测到的每种 microRNA 的相对表达水平都高度相关。
图 5.尿液和血浆中的 miRNA 图谱高度重叠。从三个不同的健康人身上采集血浆和中段尿液。使用 Norgen 的尿液外泌体 RNA 纯化试剂盒从每个尿液样本 20 mL 中分离出 RNA(类别号:47200),使用 Norgen 的血浆/血清 RNA 纯化迷你试剂盒提取 200 µL 的每个血浆样本(类别号:55000)。然后使用 Illumina TruSeq 小 RNA 文库制备试剂盒生成小 RNA 文库,随后在 Illumina MiSeq 系统上进行测序。然后对同一人血浆和尿液中的映射 miRNA 列表进行比较。维恩图显示,每个人的尿液和血浆中的 miRNA 图谱高度重叠。
图 6.尿液中其他小 RNA 物种(Piwi-Interacting)的多样性增加。从三个不同的健康人身上采集血浆和中段尿液。使用 Norgen 的尿液外泌体 RNA 纯化试剂盒从每个尿液样本 20 mL 中分离出 RNA(类别号:47200),使用 Norgen 的血浆/血清 RNA 纯化迷你试剂盒提取 200 µL 的每个血浆样本(类别号:55000)。然后使用 Illumina TruSeq 小 RNA 文库制备试剂盒生成小 RNA 文库,随后在 Illumina MiSeq 系统上进行测序。上图显示,尿液中 piwi-interacting RNA(piRNA)的相对比例一直较高。
图 7.Norgen 的总 RNA 纯化试剂盒能从 HeLa 细胞中分离出 miRNA,其多样性优于主要竞争对手。使用 Norgen 的总 RNA 纯化试剂盒和 竞争对手 Q 的领先 miRNA 试剂盒从 100 万个 HeLa 细胞中分离出包括 miRNA 在内的总 RNA,并将其应用于 MiSeq 测序仪上的 Illumina Small RNA 下一代测序。面板 A 显示,诺健总 RNA 纯化试剂盒比竞争对手能回收更多的 miRNA。特别是,在不使用苯酚的情况下,只需 20 分钟的 RNA 样本制备时间,就能以更快、更简单的程序实现更高的多样性。B 部分是检测到的 miRNA 平均 RPM(每百万读数)的散点图,用于比较 Norgen 和竞争对手的 miRNA 回收率。Norgens 总 RNA 纯化试剂盒回收的具有较高 RPM 的 miRNA 数量明显较多,如插图和面板 C 所示。
图 8.从不同体积的血浆中纯化无细胞循环 RNA 和外泌体 RNA。Norgens Plasma/Serum RNA Purification Midi Kit(类别号:56100)用于从 0.25 mL、0.75 mL 和 1.5 mL 血浆中纯化无细胞循环和外泌体 RNA。然后将 2 μL 纯化的 RNA 用作 RT-q 聚合酶链式反应的模板,以评估 (A) 家系 5S rRNA 转录本和 (B) miR-21 的扩增情况。随着样本输入量的增加,5S rRNA 转录本和 miR-21 的平均 Ct 值呈线性下降趋势。
图 9.使用 Norgens Plasma/Serum RNA Purification Midi Kit 从不断增加的血浆中纯化的 RNA 的线性度。Norgens Plasma/Serum RNA Purification Midi Kit(类别号:56100)用于从 0.25 mL、0.7 mL 和 1.5 mL 血浆中纯化 RNA。然后将 2 μL 纯化的 RNA 用作 RT-q 聚合酶链式反应的模板,以评估来自不同血浆容量的 (A) 5S rRNA 转录本和 (B) miR-21 的线性度。Norgens 血浆/血清 RNA 纯化 Midi 试剂盒能从 0.75 mL 血浆中回收 97% 的 5S rRNA 转录本和 miR-21 转录本,而 0.35 mL 血浆中的回收率仅为 97%。此外,与 0.75 mL 血浆中的含量相比,从 1.5 mL 血浆中回收了 95% 的 5S rRNA 转录本和 miR-21。
图 10.在检测人类 5S 转录本和 miR-21 时,确定血浆 RNA 样本中的抑制量。使用 Norgens Plasma/Serum RNA Purification Midi Kit(类别号:56100)从 0.25 mL、0.75 mL 和 1.5 mL 血浆中分离 RNA。在 20 µL 反转录反应和 q 聚合酶链式反应扩增反应中使用的洗脱液体积不断增加(2、4 和 8 µL),以观察 Ct 值的下降情况。随着模板量的增加,Ct 值也会增加,这清楚地表明样本中存在聚合酶链式反应抑制剂。增加反转录反应中用作模板的聚合酶链式反应输入体积不会影响 q 聚合酶链式反应扩增产生的 (A) 5S rRNA 转录本和 (B) miR-21 的 Ct 值。事实上,Ct 值会随着聚合酶链式反应输入量的增加而降低,这表明使用 Norgens 试剂盒从血浆中纯化的 RNA 不含通常存在于血浆中的常见抑制剂。
图 10.从不同体积的血浆中纯化无细胞循环 RNA 和外泌体 RNA。Norgens 血浆/血清 RNA 纯化 Maxi 试剂盒(类别号:56200)用于从 1.5 mL、3 mL 和 5 mL 血浆中纯化无细胞的循环和外泌体 RNA。然后将两毫升纯化的 RNA 用作 RT-q 聚合酶链式反应的模板,以评估 (A) 家管 5S rRNA 转录本和 (B) miR-21 的扩增情况。随着样本输入量的增加,5S rRNA 转录本和 miR-21 的平均 Ct 值呈线性下降趋势。
图 11.使用 Norgens Plasma/Serum RNA Purification Maxi Kit(诺金血浆/血清 RNA 纯化 Maxi Kit)从不断增加的血浆中纯化的 RNA 的线性度。Norgens Plasma/Serum Cell-Free Circulating and Exosomal RNA Purification Maxi Kit(类别号:56200)用于纯化 1.5 mL、3 mL 和 5 mL 血浆中的 RNA。然后将 2 μL 纯化的 RNA 用作 RT-q 聚合酶链式反应的模板,以评估来自不同血浆容量的 (A) 5S rRNA 转录本和 (B) miR-21 的线性度。诺健血浆/血清 RNA 纯化 Maxi 试剂盒能够从 3 mL 血浆中回收 92% 的 5S rRNA 转录本,而 1.5 mL 血浆中的含量仅为 92%。此外,与 3 mL 血浆中的含量相比,从 5 mL 血浆中回收了 90% 的 5S rRNA 转录本。至于 miR-21,Norgens Plasma/Serum RNA Purification Maxi 试剂盒能从 3 mL 血浆中回收 91% 的 miR-21,而 1.5 mL 血浆中的含量为 91%。此外,相对于 3 mL 血浆中的含量,从 5 mL 血浆中回收了 90% 的 miR-21。
图 12.在检测人类 5S 转录本和 miR-21 时,确定血浆 RNA 样本中的抑制量。使用 Norgens Plasma/Serum RNA Purification Maxi Kit(类别号:56200)从 1.5 mL、3 mL 和 5 mL 血浆中分离 DNA。在 20 µL 反转录反应和 q 聚合酶链式反应扩增反应中使用的洗脱液体积不断增加(2、4 和 8 µL),以观察 Ct 值的下降情况。随着模板量的增加,Ct 值也会增加,这清楚地表明样本中存在聚合酶链式反应抑制剂。增加反转录反应中用作模板的聚合酶链式反应输入体积不会影响 q 聚合酶链式反应扩增产生的 (A) 5S rRNA 转录本和 (B) miR-21 的 Ct 值。事实上,随着聚合酶链式反应输入量的增加,Ct 值往往会降低,这表明使用 Norgens 试剂盒从血浆中纯化的 RNA 不含通常存在于血浆中的常见抑制剂。
|
试剂盒规格
|
|
| 样本量范围 |
50 to 200 μL
|
|
抗凝剂(用于血浆)*
|
EDTA 或柠檬酸盐
|
| 纯化的 RNA 大小 |
所有大小,包括小 RNA(< 200 nt)
|
| 最小洗脱体积 |
10 μL
|
| 最大洗脱体积 | 25 μL |
| 完成 10 次净化所需的时间 |
15-20 分钟
|
| 平均产量** |
视样本而定
|
*本试剂盒适用于从新鲜或冷冻血清或血浆中分离 RNA。不应使用肝素采血制备的血浆样本,因为肝素会严重干扰许多下游应用,如 RT-PCR。
**请查看第 7 页,了解血浆/血清平均产量和常用 RNA 定量方法。
储存条件和产品稳定性
所有溶液都应密封保存在室温下。该试剂盒自发货之日起 2 年内保持稳定。如果发现盐沉淀,建议将裂解缓冲液 A 在 60°C 下加热 20 分钟。
Documentation
- in a timely manner that considers the person's accessibility needs due to disability; and
- at a cost that is no more than the regular cost charged to other persons